FOLH1 and hepatocellular carcinoma: However, [18F]F-PSMA-1007 shows a different biodistribution from the other PSMA-targeting radiopharmaceuticals, demonstrating higher lipophilicity and, consequently, may not be found in the ureters and bladder since its clearance is liver-dominant [53]; this characteristic makes theoretically [18F]F-PSMA-1007 less suitable for HCC imaging than the others PSMA-targeting radiopharmaceuticals.